Evidence map›Paper›PMID 18583527›Full record

ArticleMolecular cancer research : MCR2008

Tumor suppression by p53 in the absence of Atm.

S Lawrence Bailey, Kay E Gurley, Kyung Hoon-Kim, Karen S Kelly-Spratt, Christopher J Kemp

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

S Lawrence BaileyFred Hutchinson Cancer Research Center, Seattle, WA 90109-1024, USA.
Kay E Gurley
Kyung Hoon-Kim
Karen S Kelly-Spratt
Christopher J Kemp
Fred Hutch Cancer Center · US

Funding

Comparative Mouse Genomics CenterU01ES011045 · NIEHS · UNIVERSITY OF WASHINGTON · PI LADIGES, WARREN C. · 2001 to 2006
$7.2M
The Role of Double Strand Breaks in CarcinogenesisR01CA070414 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KEMP, CHRISTOPHER J · 1996 to 2006
$2.2M
NCI NIH HHS R01 CA070414NCI NIH HHS R01 CA70414NIEHS NIH HHS U01 ES011045NIEHS NIH HHS U01 ES11045
6 · The paper itself

Abstract

Oncogenes can induce p53 through a signaling pathway involving p19/Arf. It was recently proposed that oncogenes can also induce DNA damage, and this can induce p53 through the Atm DNA damage pathway. To assess the relative roles of Atm, Arf, and p53 in the suppression of Ras-driven tumors, we examined susceptibility to skin carcinogenesis in 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Atm- and p53-deficient mice and compared these results to previous studies on Arf-deficient mice. Mice with epidermal-specific deletion of p53 showed increased papilloma number and progression to malignant invasive carcinomas compared with wild-type littermates. In contrast, Atm-deficient mice showed no increase in papilloma number, growth, or malignant progression. gamma-H2AX and p53 levels were increased in both Atm(+/+) and Atm(-/-) papillomas, whereas Arf(-/-) papillomas showed much lower p53 expression. Thus, although there is evidence of DNA damage, signaling through Arf seems to regulate p53 in these Ras-driven tumors. In spontaneous and radiation-induced lymphoma models, tumor latency was accelerated in Atm(-/-)p53(-/-) compound mutant mice compared with the single mutant Atm(-/-) or p53(-/-) mice, indicating cooperation between loss of Atm and loss of p53. Although p53-mediated apoptosis was impaired in irradiated Atm(-/-) lymphocytes, p53 loss was still selected for during lymphomagenesis in Atm(-/-) mice. In conclusion, in these models of oncogene- or DNA damage-induced tumors, p53 retains tumor suppressor activity in the absence of Atm.

Indexed as

9,10-Dimethyl-1,2-benzanthraceneAnimalsAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsDNA-Binding ProteinsDNA DamageLoss of HeterozygosityMiceProtein Serine-Threonine KinasesSignal TransductionSkin NeoplasmsTumor Suppressor Protein p53Tumor Suppressor Proteins9,10-Dimethyl-1,2-benzanthraceneAtaxia Telangiectasia Mutated ProteinsAtm protein, mouseCell Cycle ProteinsDNA-Binding ProteinsProtein Serine-Threonine KinasesTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID18583527
PMCPMC2680228
OpenAlexW2082260102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.